Multiple portion tablet
Patent 6663892 Issued on December 16, 2003. Estimated Expiration Date: 
August 19, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 19, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 701438 2888382 3048526 3125491 3358687 Enzyme-containing denture cleanser tablet Compressed and formed alkaline component suitable for use in buffered aspirin product Oral garlic preparations and process for preparing same Fibre formulations Sustained release pharmaceutical preparations containing an analgesic and a decongestant InventorAssigneeApplicationNo. 10/223127 filed on 08/19/2002US Classes:424/472, Layered unitary dosage forms424/464, Tablets, lozenges, or pills424/682, Aluminum, calcium or magnesium element, or compound containing424/686, Carbonate or bicarbonate424/687, Calcium carbonate424/688, Oxide or hydroxide424/689, With stabilizer or suspending agent424/690, Aluminum hydroxide424/692, Magnesium hydroxide or oxide424/715, Carbonate424/716, Ammonium carbonate424/717, Bicarbonate514/400At imidazole ring carbonExaminersPrimary: Page, Thurman K.Assistant: George, Konata M. Attorney, Agent or FirmInternational ClassesA61K 9/24 (20060101)A61K 45/06 (20060101) A61K 45/00 (20060101) ClaimsThe invention claimed is: 1. A solid orally administrable pharmaceutical dosage form comprising: a first portion containing a therapeutically effective amount of a histamine H2 -receptor antagonist; and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. 2. The dosage form of claim 1, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR2## wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3. 3. The dosage form of claim 1, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine. 4. The dosage form of claim 1, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids. 5. A solid orally administrable pharmaceutical dosage form comprising: a first layer containing a therapeutically effective amount of a histamine H2 -receptor antagonist; and a second layer immediately adjacent the first layer without an intervening barrier layer disposed between the first layer and the second layer, the second layer containing a therapeutically effective amount of an antacid. 6. The dosage form of claim 5, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR3## wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3. 7. The dosage form of claim 5, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine. 8. The dosage form of claim 5, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids. 9. The dosage form of claim 5, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate. 10. The dosage form of claim 5, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate, and wherein the histamine H2 -receptor antagonist is famotidine. 11. The dosage form of claim 5, further comprising a third layer containing a second antacid. 12. The dosage form of claim 11, wherein the histamine H2 -receptor antagonist is famotidine, the antacid in the second layer is one of magnesium hydroxide and calcium carbonate, and the antacid in the third layer is the other of magnesium hydroxide and calcium carbonate. 13. A process of preparing a multiple layer tablet containing a histamine H2 -receptor antagonist and an antacid, comprising: blending a first active ingredient selected from the antacid and the histamine H2 -receptor antagonist with suitable excipients and/or adjuvants to form a first mixture; compressing the first mixture to form a first layer of the tablet; blending the other of the antacid and histamine H2 -receptor antagonist with excipients and/or adjuvants to form a second mixture; and compressing the second mixture directly on the first layer to form a second layer without any intervening barrier layer between the first layer and second layer. 14. The process of claim 13, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR4## wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3. 15. The process of claim 13, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine. 16. The process of claim 13, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids. 17. The process of claim 13, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate. 18. The process of claim 13, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate, and wherein the histamine H2 -receptor antagonist is famotidine. 19. The process of claim 13, further comprising a third layer containing a second antacid. 20. The process of claim 19, wherein the histamine H2 -receptor antagonist is famotidine, the antacid in the second layer is one of magnesium hydroxide and calcium carbonate, and the antacid in the third layer is the other of magnesium hydroxide and calcium carbonate. Field of SearchPREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORMTablets, lozenges, or pills Layered unitary dosage forms Aluminum, calcium or magnesium element, or compound containing Carbonate or bicarbonate Calcium carbonate Oxide or hydroxide With stabilizer or suspending agent Aluminum hydroxide Magnesium hydroxide or oxide |
